Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > NanoBio’s Vaccine Adjuvant Platform Demonstrates Robust Immunity and Cross Protection Against Influenza

Abstract:
Studies being presented at the 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2009

NanoBio’s Vaccine Adjuvant Platform Demonstrates Robust Immunity and Cross Protection Against Influenza

Ann Arbor, MI | Posted on September 8th, 2009

NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns. The company also announced that data from a large GLP toxicity study in rabbits demonstrated similarly robust immune responses without signs of toxicity or inflammation.

Data from both studies will be presented on Sunday, September 13th at 11:15 am at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at the Moscone Center, San Francisco, CA. The poster references are as follows:

Poster # G1-877: Intranasal W805EC Adjuvanted Fluzone Provides Robust Immunity and Cross-Protection in Ferrets

Poster # G1-878: A GLP Toxicity and Immunogenicity Study of NB-1008, an Intranasal W805EC-Adjuvanted-Fluzone Vaccine

NanoBio will sponsor corporate booth # 1711 at ICAAC, where information on the company's development programs for its vaccine, dermatological and anti-infective programs will be available.

####

About NanoBio Corp.
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

About NanoBio’s Vaccine Platform

NanoBio’s nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcus, anthrax, smallpox and other diseases. The company’s NanoStat™ adjuvant platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen sparing qualities; cross-protection against strains not included in the vaccine; ability to adjuvant multiple antigen types without inducing inflammation; thermal stability of the vaccine; and removing the need for needles.

NanoBio Corp. announced earlier in 2009 that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered intranasally. This Phase 1 study is ongoing.

For more information, please click here

Contacts:
Telephone: 734.302.4000
Fax: 734.302.9150

Copyright © NanoBio Corp.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A 'movie' of ultrafast rotating molecules at a hundred billion per second: A quantum wave-like nature was successfully observed in rotating nitrogen molecules July 4th, 2015

New Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment July 4th, 2015

Clues to inner atomic life from subtle light-emission shifts: Hyperfine structure of light absorption by short-lived cadmium atom isotopes reveals characteristics of the nucleus that matter for high precision detection methods July 3rd, 2015

Pioneering Southampton scientist awarded prestigious physics medal July 3rd, 2015

Nanomedicine

New Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment July 4th, 2015

Groundbreaking research to help control liquids at micro and nano scales July 3rd, 2015

Iranian Scientists Find Simple, Economic Method to Synthesize Antibacterial Nanoparticles July 2nd, 2015

Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015

Announcements

A 'movie' of ultrafast rotating molecules at a hundred billion per second: A quantum wave-like nature was successfully observed in rotating nitrogen molecules July 4th, 2015

New Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment July 4th, 2015

Clues to inner atomic life from subtle light-emission shifts: Hyperfine structure of light absorption by short-lived cadmium atom isotopes reveals characteristics of the nucleus that matter for high precision detection methods July 3rd, 2015

Pioneering Southampton scientist awarded prestigious physics medal July 3rd, 2015

Nanobiotechnology

Groundbreaking research to help control liquids at micro and nano scales July 3rd, 2015

Engineering the world’s smallest nanocrystal July 2nd, 2015

Nanometric sensor designed to detect herbicides can help diagnose multiple sclerosis June 23rd, 2015

Newly-Developed Biosensor in Iran Detects Cocaine Addiction June 23rd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project